# Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

> **NCT00385593** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 654 (actual)

## Conditions studied

- Asthma, Bronchial

## Interventions

- **DRUG:** Symbicort (budesonide/formoterol) Turbuhaler
- **DRUG:** Conventional treatment

## Key facts

- **NCT ID:** NCT00385593
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-10
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2010-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385593, "Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00385593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*